Compass Pathways accelerates potential COMP360 launch timeline by 9–12 months with NDA submission plans in Q3 2026

Q3 2025 Management View CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we ...
Seeking Alpha

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...
Business Insider

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational ...

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health ...
Morningstar

Compass Pathways to Participate in December Investor Conferences

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who ...
Business Insider

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who ...
Business Wire

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
Nasdaq

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

COMPASS Pathways plc (NASDAQ:CMPS) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call Transcript November 4, 2025 COMPASS Pathways plc misses on earnings expectations. Reported EPS is ...
Nasdaq

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
FOX8 Cleveland

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
Seeking Alpha

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...
Morningstar

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731175223/en/ The articles, information, and content displayed on this webpage ...